What is Myhep All Tablet?

Myhep All Tablet is a combination drug containing two antiviral medicines - Sofosbuvir and Velpatasvir. Sofosbuvir prevents HCV from multiplying in the body by blocking an enzyme needed for viral replication. Velpatasvir also hinders viral replication but works in a slightly different way by inhibiting HCV proteins.

Together, these two direct-acting antiviral agents (DAAs) pack a strong punch against multiple HCV genotypes. Myhep All tablets have demonstrated high cure rates of over 95% across HCV genotypes in clinical trials.

How Does Myhep All Work Against HCV?

Myhep All leverages the synergistic effect of Sofosbuvir and Velpatasvir. Each DAA attacks HCV via different mechanisms, making it extremely difficult for the virus to resist both drugs simultaneously. This not only increases the potency of the treatment but also reduces the risk of HCV developing resistance.

Key Benefits of Myhep All Tablets:

• High efficacy against diverse HCV genotypes

• Convenient once-daily oral dosing

• Excellent tolerability and safety profile

• Can treat patients with compensated cirrhosis

Myhep All Tablet is an important new tool for combating chronic hepatitis C by combining two powerful DAA medications. Its convenient dosing, impressive cure rates, and safety make it an attractive therapy option for HCV patients. By attacking HCV replication at multiple points, Myhep All can resolve HCV infection where previous treatments have failed.